Applied Clinical Trials Publishes CRO Analytics Research on Measuring Clinical Trial Quality

Article explores first scientifically-validated method for measuring clinical trial performance and quality.

New Hope, PA, January 15, 2015 –

CRO Analytics, the leading provider of validated clinical trial performance data is pleased to announce that Applied Clinical Trials published “The Quality of Clinical Trials,” by Dr. Michael Howley, Chief Science Officer of CRO Analytics and Associate Professor at Drexel University and CRO Analytics CEO, Peter Malamis. The article is the first of a series that will review the findings of the first scientific measurement of quality in clinical trials developed by CRO Analytics.

Clinical trials are a $71 billion industry that offer services critical to the business success of their sponsors and the health and welfare of patients. Yet, there are no widely accepted, scientifically-validated measures to track the quality of clinical trials. To address this, CRO Analytics developed a methodology for measuring performance and quality of clinical trials.

“The lack of scientific quality measurement contributes to clinical trial industry’s struggle to address problems like cost overruns and adherence to timelines,” stated Malamis. “Over the course of four years and in collaboration with Applied Clinical Trials and Drexel University, we developed and deployed a completely new approach and cloud-based application designed to bring the industry not simply a new tool but practical, actionable insights. While future articles will delve into specific finding related to each stage of clinical trials, the initial article reviews findings related to the current state of trial quality.

Howley commented that “the variation in quality by phase, the number of subjects and investigative sites as indicators of just how complex the challenge of improving trials is and requires an approach as scientifically rigorous as the trials themselves.”

Key findings of the research include:

  • Clinical trial quality varies by phase of the trial, with Phase II having the highest and most consistent quality ratings.
  • Quality varied by the number of subjects and investigative sites. Quality generally declines as the number of subjects increases, and decreases as the number of sites increase until about 75 sites.
  • Quality increases as number of patients per site increases up to about 15 subjects per site and then declines.

The full article is accessible here:

About CRO Analytics

CRO Analytics provides the only validated performance data collection system for clinical trials, providing straightforward access to quality benchmarking, key performance drivers and predictive analytics in an intuitive format – making clinical research better, faster and less expensive. To learn more, please visit

Media Contact:
Margretta Feuer
Sagefrog Marketing Group, LLC

# # #